Free Trial

SCYNEXIS (SCYX) Competitors

SCYNEXIS logo
$1.20 -0.06 (-4.76%)
(As of 11/15/2024 ET)

SCYX vs. ETTX, ADAP, SCPH, DRUG, GALT, GOSS, DMAC, MDWD, SGMT, and NBTX

Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Entasis Therapeutics (ETTX), Adaptimmune Therapeutics (ADAP), scPharmaceuticals (SCPH), Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), Gossamer Bio (GOSS), DiaMedica Therapeutics (DMAC), MediWound (MDWD), Sagimet Biosciences (SGMT), and Nanobiotix (NBTX). These companies are all part of the "medical" sector.

SCYNEXIS vs.

SCYNEXIS (NASDAQ:SCYX) and Entasis Therapeutics (NASDAQ:ETTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

SCYNEXIS has higher revenue and earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SCYNEXIS$140.14M0.32$67.04M-$0.74-1.62
Entasis Therapeutics$7M14.97-$47.14M-$1.12-1.96

SCYNEXIS has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Entasis Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

In the previous week, SCYNEXIS had 6 more articles in the media than Entasis Therapeutics. MarketBeat recorded 6 mentions for SCYNEXIS and 0 mentions for Entasis Therapeutics. SCYNEXIS's average media sentiment score of 1.06 beat Entasis Therapeutics' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company Overall Sentiment
SCYNEXIS Positive
Entasis Therapeutics Neutral

Entasis Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. SCYNEXIS's return on equity of -66.21% beat Entasis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SCYNEXIS-425.41% -66.21% -38.84%
Entasis Therapeutics N/A -145.48%-103.75%

SCYNEXIS received 409 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 64.86% of users gave Entasis Therapeutics an outperform vote.

CompanyUnderperformOutperform
SCYNEXISOutperform Votes
505
70.04%
Underperform Votes
216
29.96%
Entasis TherapeuticsOutperform Votes
96
64.86%
Underperform Votes
52
35.14%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Entasis Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 6.9% of Entasis Therapeutics shares are owned by institutional investors. 2.9% of SCYNEXIS shares are owned by company insiders. Comparatively, 6.5% of Entasis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

SCYNEXIS beats Entasis Therapeutics on 14 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCYX vs. The Competition

MetricSCYNEXISPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$45.54M$6.53B$5.15B$8.74B
Dividend YieldN/A8.15%5.18%4.08%
P/E Ratio-1.624.4062.6013.00
Price / Sales0.32377.651,277.9088.72
Price / Cash0.6351.2139.7935.27
Price / Book0.789.636.455.92
Net Income$67.04M$154.43M$119.73M$225.73M
7 Day Performance-8.40%-9.46%-5.13%-1.34%
1 Month Performance-20.53%-7.27%-2.71%1.15%
1 Year Performance-25.93%28.13%31.08%24.02%

SCYNEXIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCYX
SCYNEXIS
2.4281 of 5 stars
$1.20
-4.8%
N/A-24.1%$45.54M$140.14M-1.6260Positive News
ETTX
Entasis Therapeutics
N/A$2.19
flat
N/A+0.0%$104.80M$7M-1.9651
ADAP
Adaptimmune Therapeutics
2.1677 of 5 stars
$0.77
-2.9%
N/A+17.3%$197.05M$60.28M-2.20449Analyst Forecast
Analyst Revision
News Coverage
SCPH
scPharmaceuticals
4.013 of 5 stars
$3.90
-0.8%
N/A-31.1%$195.11M$24.05M-2.5030Analyst Forecast
Analyst Revision
News Coverage
DRUG
Bright Minds Biosciences
2.3947 of 5 stars
$42.41
+6.9%
N/A+2,994.5%$187.88MN/A-62.37N/AShort Interest ↓
Positive News
Gap Down
GALT
Galectin Therapeutics
1.8669 of 5 stars
$3.00
+1.4%
N/A+46.6%$186.84MN/A-3.809Analyst Downgrade
Analyst Revision
News Coverage
Positive News
GOSS
Gossamer Bio
4.3817 of 5 stars
$0.81
-4.1%
N/A-10.3%$184.25MN/A-2.54180Short Interest ↓
Analyst Revision
News Coverage
DMAC
DiaMedica Therapeutics
2.2154 of 5 stars
$4.32
+0.2%
N/A+68.5%$184.24MN/A-8.1520Analyst Forecast
News Coverage
MDWD
MediWound
2.0214 of 5 stars
$16.83
-0.5%
N/A+93.2%$181.60M$18.69M-7.7980Positive News
SGMT
Sagimet Biosciences
2.1282 of 5 stars
$5.92
-0.3%
N/A+103.0%$181.57M$2M0.008Analyst Forecast
News Coverage
Gap Down
NBTX
Nanobiotix
2.3844 of 5 stars
$3.83
-5.0%
N/A-34.5%$180.51M$39.18M0.00100News Coverage

Related Companies and Tools


This page (NASDAQ:SCYX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners